MARKET

LPCN

LPCN

Lipocine
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5499
+0.0199
+3.75%
Closed 19:59 01/21 EST
OPEN
0.5350
PREV CLOSE
0.5300
HIGH
0.5500
LOW
0.5022
VOLUME
1.35M
TURNOVER
--
52 WEEK HIGH
3.450
52 WEEK LOW
0.3200
MARKET CAP
13.97M
P/E (TTM)
-1.0007
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of LPCN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

LPCN News

  • DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Lipocine Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  • ACCESSWIRE.01/14 16:25
  • LPCN FINAL DEADLINE TODAY: Rosen, a Leading Law Firm, Reminds Lipocine Inc. Investors of Important January 14th Deadline in Securities Class Action LPCN
  • GlobeNewswire.01/14 14:42
  • TUESDAY DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Lipocine, Inc. and Encourages Investors to Contact the Firm
  • GlobeNewswire.01/14 00:35
  • LPCN FINAL DEADLING: ROSEN, A TOP FIRM, Reminds Lipocine Inc. Investors of Important January 14 Deadline in Securities Class Action - LPCN
  • ACCESSWIRE.01/13 22:30

More

Industry

Biotechnology & Medical Research
-0.61%
Pharmaceuticals & Medical Research
-0.38%

Hot Stocks

Name
Price
%Change

About LPCN

Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company's additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip'ral promicellar drug delivery technology platform. Lip'ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.
More

Webull offers Lipocine Inc (LPCN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.